Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHPS | P49366 | 3/20 | 0.52 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.46 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9148456 | 0.87 | CYP11B2 (0.47) | DHPSTRPV6TP53MAPTALDH1A1 | |
| SCHEMBL2025367 | 0.85 | DHPS (0.53) | DHPSTRPV6TNIKCYP11B1CYP11B2 | |
| SCHEMBL25612013 | 0.81 | DHPS (0.55) | DHPSLMNATP53MAPTALDH1A1 | |
| SCHEMBL19967147 | 0.81 | CYP11B2 (0.58) | LMNARAB9ATDP1FFAR4CYP19A1 | |
| SCHEMBL2026710 | 0.79 | HDAC1 (0.47) | DHPSTNIKMAPK1HRH3MEN1 | |
| SCHEMBL1002943 | 0.78 | ADAM17 (0.57) | TNIKLMNAMAPTALDH1A1MAPK1 | |
| SCHEMBL9141408 | 0.78 | ADAM17 (0.43) | MAPK1CYP19A1CYP11B1CYP11B2HDAC4 | |
| SCHEMBL17615711 | 0.78 | KDM4C (0.42) | DHPSTNIKMAPK1 | |
| SCHEMBL2025909 | 0.78 | TNIK (0.46) | DHPSTNIKMAPK1MEN1KMT2A | |
| SCHEMBL2025564 | 0.77 | MEN1 (0.44) | TNIKALDH1A1MEN1KMT2AHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3509588-B1 | BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | INTEGRAL HEALTH INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210347768-A1 | BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | VALO HEALTH, INC. | 2021-11-11 | — | — | US | disclosed |
| US-10865201-B2 | Bicyclic compounds useful as GPR120 modulators | VALO HEALTH, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20190218208-A1 | BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | VALO HEALTH, INC. | 2019-07-18 | — | — | US | disclosed |
| WO-2018049328-A1 | BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | NUMERATE, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865201-B2 | Bicyclic compounds useful as GPR120 modulators | GPR119, GPR180, GPR65 | DHPS 4408/4885TRPV6 363/4885TNIK 3452/4885 |
| US-20190218208-A1 | BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | GPR119, GPR180, GPR65 | DHPS 4408/4885TRPV6 363/4885TNIK 3452/4885 |
| US-20210347768-A1 | BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | GPR119, GPR180, GPR65 | DHPS 4408/4885TRPV6 363/4885TNIK 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.